Since then, in addition to cardiovascular functions regulated by the systemic RAS, the potential role of local RAS in malignancy has been recognised (Egami et al, 2003; Juillerat-Jeanneret et al, 2004; Ager et al, 2008; George et al, 2010), and an increasing body of evidence in experimental studies suggests that Ang II could act on tumour progression via two main and different mechanisms; the promotion of cancer proliferation and/or neovascularisation through AT1R (Greco et al, 2003; Arrieta et al, 2005; Khakoo et al, 2008). The gene discussed is AGT; the disease is neoplasm.